Clinical Debates and Consensus Recommendations on the Use of Antiangiogenic Agents in Lung Cancer: A Focus on the Elderly Patient
This activity contains:
- CME-Certified Virtual Grand Rounds
Release Date: 3/27/2017
Expiration Date: 3/26/2018
Estimated time to complete activity: 30 minutes
The goal of this activity is to provide clinicians with appropriate context and practical application of the latest evidence-based data on the use of antiangiogenic agents in the treatment of non–small cell lung cancer in older patient populations.
Discussions will focus on the angiogenesis pathway in NSCLC, the implementation of vascular endothelial growth factor (VEGF) inhibitors in older patients with NSCLC and its controversies, clinical results with use of VEGF inhibitors in older patients, and factors causing unintended treatment bias. An expert thought leader will provide insights in support of their perspectives on the discussion points.
This activity is based upon outcomes from a prior predictive modeling analysis of a live grand rounds series, and features evidence-based updates and expert consensus recommendations to address specific educational gaps highlighted as a result of the predictive modeling exercise. The activity focused on the drivers identified that influence poor performance, and provides the evidence to assist learners in overcoming said drivers and gaps, apply this information to clinical situations, and encourage steps to close these remaining gaps in their own practices.
This activity is designed for medical oncologists, thoracic oncologists, surgical oncologists, radiation oncologists, and other healthcare providers who treat or manage non–small cell lung cancer.
At the conclusion of this activity, participants should be better able to:
- Review the role of angiogenesis in the progression of non–small cell lung cancer (NSCLC)
- Utilize factors important for determining the use of antiangiogenic agents for the treatment of NSCLC in older patients such as performance status, polypharmacy, and comorbidities
- Address emerging evidence on the efficacy of various antiangiogenic agents in older patients with NSCLC
- Appropriately manage adverse effects associated with the use of antiangiogenic agents in older patients with NSCLC
- Identify common misperceptions about elderly patients with NSCLC and contrast with evidence-based statistics
Mark A. Socinski, MD
Physician Continuing Medical Education
The Postgraduate Institute for Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Name of Faculty or Presenter||Reported Financial Relationship|
Mark A. Socinski, MD
Contracted research: AVEO Pharmaceuticals, Inc; Bristol-Myers Squibb Co; Celgene Corp; Clovis Oncology; Genentech, Inc; Novartis Pharmaceuticals Corp; Pfizer, Inc; Synta Pharmaceuticals Corp; Speakers' bureau: Celgene Corp; Genentech, Inc
The following PIM planners and managers, Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, RN, BSN; and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The following AXIS planners and managers, Linda Gracie-King, MS; Ronald Viggiani, MD; and Jocelyn Timko, BS, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this activity. During the period 3/27/2017, through, 3/26/2018, participants must read the learning objectives and faculty disclosures and study the educational activity.
Upon successfully completing the post-test with a score of 75% or better and the activity evaluation, your certificate will be made available immediately.
|MEDIA SYSTEM REQUIREMENTS|
Safeguards Against Commercial Bias
Postgraduate Institute for Medicine and AXIS affirm that the content and format of the CME activities and related materials promote improvements and quality in healthcare and do not promote a specific proprietary business interest of a commercial entity. To this end, Postgraduate Institute for Medicine and AXIS employ several strategies to ensure the absence of commercial bias, including, but not limited to, review of all planned content for CME activities jointly sponsored by Postgraduate Institute for Medicine and AXIS to ensure adherence to the Accreditation Council for Continuing Medical Education’s content validation statements, and resolution of any actual or perceived conflicts of interest that exist. We employ three metrics as we review materials:
1. Fair balance
a. Recommendations or emphasis must fairly represent and be based on a reasonable and valid interpretation of the information available on the subject matter
b. No single product or service is overrepresented when other equal competing products or services are available for inclusion
2. Scientific objectivity of studies mentioned in the materials or used as the basis for content
3. Appropriateness of patient care recommendations made to learners
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This activity is supported by an independent educational grant from Genentech and by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com
There is no fee for this educational activity.
This activity is jointly provided by
To contact PIM please visit: www.pimed.com
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC
- 0.50 Attendance